Mosaic trisomy 12 syndrome

Mosaic trisomy 12 syndrome (Orphanet code 1698) is an extremely rare chromosomal disorder in which some cells of the body contain three copies of chromosome 12 instead of the usual two, while other cells have the normal two copies. This mosaic pattern arises from a postzygotic (after fertilization) nondisjunction event, meaning the chromosomal abnormality is not present in all cells. Because only a proportion of cells carry the extra chromosome, the severity and range of clinical features can vary considerably from patient to patient, depending on the percentage and distribution of trisomic cells across different tissues. The condition typically presents at birth or during infancy with a combination of dysmorphic facial features, growth retardation, and intellectual disability of variable degree. Reported clinical features include a broad or flat nasal bridge, abnormal ears, short neck, congenital heart defects, skeletal anomalies, and abnormalities of the hands and feet such as clinodactyly or syndactyly. Some patients may also exhibit pigmentary skin anomalies following the lines of Blaschko, reflecting the mosaic distribution of abnormal cells. Organ involvement can include the cardiovascular, musculoskeletal, and central nervous systems. There is no specific cure or targeted therapy for mosaic trisomy 12 syndrome. Management is supportive and symptomatic, tailored to the individual's specific clinical manifestations. This may include surgical correction of congenital heart defects, orthopedic interventions for skeletal anomalies, early developmental intervention programs, speech therapy, and special education support. Regular follow-up with a multidisciplinary team including geneticists, cardiologists, and developmental pediatricians is recommended. Genetic counseling is advised for affected families, although the condition is generally considered to arise sporadically and recurrence risk is very low.

Common questions about Mosaic trisomy 12 syndrome